Repligen (NASDAQ:RGEN) Issues FY 2025 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 1.670-1.760 for the period, compared to the consensus EPS estimate of 1.710. The company issued revenue guidance of $685.0 million-$710.0 million, compared to the consensus revenue estimate of $692.8 million.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity Group increased their target price on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday. Finally, JPMorgan Chase & Co. increased their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $183.36.

Repligen Stock Down 2.3 %

Shares of Repligen stock opened at $158.99 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a 1 year low of $113.50 and a 1 year high of $203.13. The firm’s 50-day moving average is $155.22 and its two-hundred day moving average is $148.79. The stock has a market cap of $8.91 billion, a price-to-earnings ratio of -311.75, a PEG ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. As a group, research analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.